| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.11 | 0.4 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.051 | 0.4 |